Sotatercept is in clinical development for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare condition causing high blood pressure in the lungs. In PAH, the arteries in the lungs become thickened and stiff meaning the arteries cannot stretch as well to allow blood to flow through. This makes it harder for the heart to bump blood through the arteries leading to high blood pressure and weakening of the heart. PAH can worsen over time and cause several problems including heart failure and blood clots. It often leads to limited physical activity and reduced life expectancy. Current treatments slow disease progression. However, the low survival rate highlights the need for therapies targeting alternative pathways.
Sotatercept for treating pulmonary arterial hypertension
Sotatercept is in clinical development for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare condition causing high blood pressure in the lungs. In PAH, the arteries in the lungs become thickened and stiff meaning the arteries cannot stretch as well to allow blood to flow through.